5,6-dihydro-5-methyl-6-oxo-4H-imidazo<1,5-a><1,4>benzodiazepine-3-carbonitrile | 78756-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 5,6-dihydro-5-methyl-6-oxo-4H-imidazo<1,5-a><1,4>benzodiazepine-3-carbonitrile
• 英文别名: 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carbonitrile；3-cyano-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine；5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carbonitrile；5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carbonitrile
• CAS: 78756-07-7
• 化学式: C₁₃H₁₀N₄O
• 分子量: 238.249
• InChiKey: WTCNIQKFPRTYES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  61.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,6-dihydro-5-methyl-6-oxo-4H-imidazo<1,5-a><1,4>benzodiazepine-3-carbonitrile 在 盐酸羟胺 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 生成 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxamidoxime
  参考文献：
  名称：

  新型苯并二氮杂receptor受体部分激动剂：恶二唑基咪唑并苯并二氮杂s。

  摘要：

  报道了一系列与苯二氮卓拮抗剂Ro 15-1788（2a）有关的咪唑基苯并二氮杂卓的恶二唑衍生物的合成和生化评估。尽管恶二唑环被看作是酯键的等排替代物，但观察到结构活性趋势上的显着差异。具体而言，相对于相应的酯，恶二唑9-12始终具有增加的受体功效（通过测量GABA位移证明）。另外，与经典的激动剂如地西epa形成鲜明对比的是，通过7-而不是8-卤素取代基增强了对苯并二氮杂receptor受体的亲和力。根据最初基于2a的X射线结构的六点受体结合模型讨论了结果。为了比较，确定了分别具有6-氧代和6-苯基基团的两种代表性恶二唑衍生物10h和12o的晶体结构，并将数据纳入了改良的结合模型中，以说明这些化合物的更高功效。结论是2a的拮抗行为取决于酯羰基氧的氢键受体性质，而对于恶二唑系列，该位点位于咪唑氮上。

  DOI：

  10.1021/jm00130a010
• 作为产物：
  描述：

  4-甲基-3,4-二氢-1h-苯并[e][1,4]二氮杂卓-2,5-二酮 在 吡啶 、 sodium hydroxide 、 氨 、 氯甲酸乙酯 、 三乙胺 、 三氟乙酸酐 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 18.0h， 生成 5,6-dihydro-5-methyl-6-oxo-4H-imidazo<1,5-a><1,4>benzodiazepine-3-carbonitrile
  参考文献：
  名称：

  新型苯并二氮杂receptor受体部分激动剂：恶二唑基咪唑并苯并二氮杂s。

  摘要：

  报道了一系列与苯二氮卓拮抗剂Ro 15-1788（2a）有关的咪唑基苯并二氮杂卓的恶二唑衍生物的合成和生化评估。尽管恶二唑环被看作是酯键的等排替代物，但观察到结构活性趋势上的显着差异。具体而言，相对于相应的酯，恶二唑9-12始终具有增加的受体功效（通过测量GABA位移证明）。另外，与经典的激动剂如地西epa形成鲜明对比的是，通过7-而不是8-卤素取代基增强了对苯并二氮杂receptor受体的亲和力。根据最初基于2a的X射线结构的六点受体结合模型讨论了结果。为了比较，确定了分别具有6-氧代和6-苯基基团的两种代表性恶二唑衍生物10h和12o的晶体结构，并将数据纳入了改良的结合模型中，以说明这些化合物的更高功效。结论是2a的拮抗行为取决于酯羰基氧的氢键受体性质，而对于恶二唑系列，该位点位于咪唑氮上。

  DOI：

  10.1021/jm00130a010

文献信息

• Oxazolyl- and thiazolylimidazo-benzo- and thienodiazepines and their use
  申请人：Hoffmann-La Roche Inc.

  公开号：US05885986A1

  公开（公告）日：1999-03-23

  The invention is concerned with basically-substituted imidazodiazepinones of the formula: ##STR1## wherein A and the two carbon atoms denoted by .alpha. and .beta. together signify: ##STR2## Q signifies one of the residues: ##STR3## R.sup.1 and R.sup.2 each signify hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower hydroxyalkyl, lower alkoxy-lower alkyl, (C.sub.3 -C.sub.6)-cycloalkyl, (C.sub.3 -C.sub.6)-cycloalkyl-lower alkyl, amino-lower alkyl, lower alkylamino-lower alkyl, di-lower alkylamino-lower alkyl or aryl-lower alkyl or together with the nitrogen atom signify a 5- to 8-membered heterocycle optionally containing a further hetero atom or a fused benzene ring; R.sup.3 signifies hydrogen and R.sup.4 signifies lower alkyl or R.sup.3 and R.sup.4 together signify a di- or trimethylene group and; R.sup.5 and R.sup.6 each signify hydrogen, halogen, trifluoromethyl, lower alkoxy or nitro; with the carbon atom denoted by .gamma. having the S-configuration when R.sup.3 is different from hydrogen, and pharmaceutically acceptable acid addition salts thereof. These compounds can be used as anxiolytic and/or anticonvulsant and/or muscle relaxant and/or sedative-hypnotic active substances.

  这项发明涉及基本取代的咪唑二氮杂环酮，化学式如下：##STR1## 其中A和由α和β表示的两个碳原子一起表示：##STR2## Q表示以下残基之一：##STR3## R.sup.1和R.sup.2各自表示氢、低烷基、低烯基、低炔基、低羟基烷基、低烷氧基-低烷基、(C.sub.3 -C.sub.6)-环烷基、(C.sub.3 -C.sub.6)-环烷基-低烷基、氨基-低烷基、低烷基氨基-低烷基、二低烷基氨基-低烷基或芳基-低烷基，或者与氮原子一起表示含有进一步杂原子或融合苯环的5-至8-成员杂环；R.sup.3表示氢，R.sup.4表示低烷基，或R.sup.3和R.sup.4一起表示二或三亚甲基基团；R.sup.5和R.sup.6各自表示氢、卤素、三氟甲基、低烷氧基或硝基；由γ表示的碳原子在R.sup.3不是氢时具有S构型，及其药用可接受的酸盐。这些化合物可用作抗焦虑、抗惊厥、肌肉松弛和/或催眠镇静活性物质。
• Imidazodiazepine derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US04316839A1

  公开（公告）日：1982-02-23

  Imidazodiazepine derivatives of the formula ##STR1## wherein A together with the two carbon atoms denoted as .alpha. and .beta. is selected from the group consisting of ##STR2## the dotted line represents the double bond present in groups (a) and (b), D is >C.dbd.O or >C.dbd.S, R.sup.1 is selected from the group consisting of cyano, lower alkanoyl and a group of the formula --COOR.sup.4, R.sup.4 is selected from the group consisting of methyl, ethyl, isopropyl and 2-hydroxyethyl, R.sup.5 is selected from the group consisting of hydrogen, trifluoromethyl and halogen and R.sup.6 is selected from the group consisting of hydrogen, trifluoromethyl, halogen and lower alkyl and either R.sup.2 is hydrogen and R.sup.3 is hydrogen or lower alkyl or R.sup.2 and R.sup.3 together are trimethylene or propenylene and the carbon atom denoted as .gamma. has the S- or R,S-configuration, and pharmaceutically acceptable salts thereof are presented and have utility for antagonizing the central-depressant, muscle relaxant, ataxic, blood pressure-lowering and respiratory-depressant properties of 1,4-benzodiazepines which have tranquillizing activity. They can be used, for example, as antidotes in the case of intoxications in which excessive intake of 1,4-benzodiazepines which have tranquillizing participates, or for shortening an anaesthesia induced by such 1,4-benzodiazepines. They can also be used for suppressing the activities on the central nervous system of 1,4-benzodiazepines used in other fields of indication, for example of schistosomicidally-active 1,4-benzodiazepines such as (+)-5-(o-chlorophenyl)-1,3-dihydro-3-methyl-7-nitro-2H-1,4-benzodiazepin-2 -one. Also presented are processes to produce the imidazodiazepine derivatives and intermediates therefor.

  咪唑二氮杂环己烯衍生物的公式为##STR1##其中A与两个碳原子α和β一起从##STR2##中选择，虚线代表(a)和(b)中存在的双键，D为>C.dbd.O或>C.dbd.S，R.sup.1从氰基，较低的烷酰基和公式--COOR.sup.4的基团中选择，R.sup.4从甲基，乙基，异丙基和2-羟乙基中选择，R.sup.5从氢，三氟甲基和卤素中选择，R.sup.6从氢，三氟甲基，卤素和较低烷基中选择，R.sup.2为氢，R.sup.3为氢或较低烷基，或者R.sup.2和R.sup.3一起为三甲亚基或丙烯亚基，所述的碳原子γ具有S-或R,S-构型，及其药学上可接受的盐，用于对抗具有镇静活性的1,4-苯二氮杂环己烷的中枢抑制、肌肉松弛、共济失调、降低血压和呼吸抑制特性。它们可以用作例如，在过量摄入具有镇静活性的1,4-苯二氮杂环己烷的中毒情况下的解毒剂，或者缩短由这些1,4-苯二氮杂环己烷引起的麻醉。它们还可用于抑制其他适应领域中使用的1,4-苯二氮杂环己烷对中枢神经系统的活性，例如对于片尾蚴活性的1,4-苯二氮杂环己烷，如(+)-5-(邻氯苯基)-1,3-二氢-3-甲基-7-硝基-2H-1,4-苯二氮杂环己烷-2-酮。还提供了生产咪唑二氮杂环己烯衍生物及其中间体的方法。
• Oxadiazolyl-imidazo-[1,4]benzodiazepines and their use in treatment of
  申请人：A/S Ferrosan

  公开号：US04507313A1

  公开（公告）日：1985-03-26

  New oxadiazolyl-imidazo-[1,4]benzodiazepine derivatives having benzodiazepine receptor activity have the formula ##STR1## R' is hydrogen, chlorine, fluorine or nitro in the 7- or 8-position, R.sup.1 is hydrogen or lower alkyl of up to 3 carbon atoms, R.sup.3 is the oxadiazolyl grouping of the formula ##STR2## wherein R" is lower alkyl with up to 3 carbon atoms and A B is a grouping of the formula ##STR3## wherein R.sup.5 is hydrogen or methyl and R'" is hydrogen or chlorine. The compounds possess valuable pharmacological properties. In particular, they act on the central nervous system and are suitable for use in psychopharmaceutical preparations.

  具有苯二氮平受体活性的新型噁二唑基咪唑[1,4]苯并二氮平衍生物的化学式为：##STR1##其中，R'为7-或8-位的氢、氯、氟或硝基，R1为1至3个碳原子的低烷基或氢，R3为下列式子的噁二唑基团：##STR2##其中，R"为1至3个碳原子的低烷基，AB为下列式子的基团：##STR3##其中，R5为氢或甲基，R'"为氢或氯。这些化合物具有有价值的药理学特性，特别是对中枢神经系统有作用，适用于精神药物制剂。
• Process for preparing imidazodiazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04363762A1

  公开（公告）日：1982-12-14

  Imidazodiazepine derivatives of the formula ##STR1## wherein A together with the two carbon atoms denoted as .alpha. and .beta. is selected from the group consisting of: ##STR2## the dotted line represents the double bond present in groups (a) and (b), D is >C.dbd.O or >C.dbd.S, R.sup.1 is selected from the group consisting of cyano, lower alkanoyl and a group of the formula --COOR.sup.4, R.sup.4 is selected from the group consisting of methyl, ethyl, isopropyl and 2-hydroxyethyl, R.sup.5 is selected from the group consisting of hydrogen, trifluoromethyl and halogen and R.sup.6 is selected from the group consisting of hydrogen, trifluoromethyl, halogen and lower alkyl and either R.sup.2 is hydrogen and R.sup.3 is hydrogen or lower alkyl or R.sup.2 and R.sup.3 together are trimethylene or propenylene and the carbon atom denoted as .gamma. has the S- or R,S-configuration, and pharmaceutically acceptable salts thereof are presented and have utility for antagonising the central-depressant, muscle relaxant, ataxic, blood pressure-lowering and respiratory-depressant properties of 1,4-benzodiazepines which have tranquillising activity. They can be used, for example, as antidotes in the case of intoxications in which excessive intake of 1,4-benzodiazepines which have tranquillising participates, or for shortening an anaesthesia induced by such 1,4-benzodiazepines. They can also be used for suppressing the activities on the central nervous system of 1,4-benzodiazepines used in other fields of indication, for example of schistosomicidally-active 1,4-benzodiazepines such as (+)-5-(o-chlorophenyl)-1,3-dihydro-3-methyl-7-nitro-2H-1,4-benzodiazepin-2 -one. Also presented are processes to produce the imidazodiazepine derivatives and intermediates therefor.

  本发明涉及式（I）的咪唑二氮杂苯衍生物，其中A与表示为α和β的两个碳原子一起从以下组中选择：##STR2##其中虚线表示(a)和(b)中存在的双键，D是>C.dbd.O或>C.dbd.S，R.sup.1从以下组中选择：氰基，低烷酰基和公式--COOR.sup.4的基团，R.sup.4从甲基，乙基，异丙基和2-羟乙基的组中选择，R.sup.5从氢，三氟甲基和卤素的组中选择，R.sup.6从氢，三氟甲基，卤素和低烷基的组中选择，且R.sup.2为氢且R.sup.3为氢或低烷基，或者R.sup.2和R.sup.3一起为三亚甲基或丙烯亚甲基，表示为γ的碳原子具有S-或R，S-构型。还提供了其药学上可接受的盐，并具有对具有镇静作用的1,4-苯二氮䓬类化合物的中枢抑制、肌肉松弛、共济失调、降低血压和呼吸抑制特性的拮抗作用。例如，在过量摄入具有镇静作用的1,4-苯二氮䓬类药物的中毒情况下，它们可以用作解毒剂，或者用于缩短由这些1,4-苯二氮䓬类药物引起的麻醉。它们还可用于抑制用于其他适应症领域的1,4-苯二氮䓬类药物对中枢神经系统的活性，例如对血吸虫杀虫活性的1,4-苯二氮䓬类药物，如(+)-5-(o-氯苯基)-1,3-二氢-3-甲基-7-硝基-2H-1,4-苯二氮䓬啶-2-酮。还提供了制备咪唑二氮杂苯衍生物及其中间体的方法。
• Oxadiazolylimidazobenzodiazepine, compositions, and method
  申请人：AS Ferrosan

  公开号：US04622321A1

  公开（公告）日：1986-11-11

  The application discloses a novel benzodiazepine agonist compound, namely, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imida zo [1,5-a][1,4]benzodiazepine, pharmaceutical compositions thereof, and a method of ameliorating central nervous system ailments therewith, especially convulsions and anxiolytic states. A novel intermediate and process for its production are also disclosed.

  该申请公开了一种新型苯二氮平激动剂化合物，即3-(5-环丙基-1,2,4-噁二唑-3-基)-5,6-二氢-5-甲基-6-氧代-4H-咪唑[1,5-a][1,4]苯二氮平，以及其制药组合物和通过其改善中枢神经系统疾病，特别是惊厥和抗焦虑状态的方法。还公开了一种新型中间体及其制备方法。